<DOC>
	<DOCNO>NCT00370630</DOCNO>
	<brief_summary>In study intend evaluate compare outcomes intravitreal avastin versus avastin triamcinolone improve visual acuity macular edema late complication CRVO like NVI NVG .</brief_summary>
	<brief_title>Intravitreal Avastin Versus Intravitreal Avastin Triamcinolone Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description>Central retinal vein occlusion ( CRVO ) common retinal vascular disorder potentially complication like reduce vision result extensive intraretinal hemorrhage , retinal ischemia persistent macular edema neovascular glaucoma secondary iris neovascularization . Macular edema common cause severe visual loss branch retinal vein occlusion ( BRVO ) central retinal vein occlusion ( CRVO ) . Natural history data indicate CRVO patient present poor visual acuity ( _20/200 ) 80 % chance leave visual acuity le 20/200 final visit , whether CRVO ischemic nonischemic presentation . Treatments target secondary effect venous occlusion , grid laser photocoagulation macular edema prophylactic panretinal laser photocoagulation nonperfused CRVO , show ineffective improve visual acuity Central Vein Occlusion Study ( CVOS ) . Although panretinal photocoagulation advocate reduce risk neovascular glaucoma patient ischemic CRVO , recent clinical trial fail demonstrate significant benefit laser photocoagulation treatment macular edema due CRVO . A number treatment option sometimes used case CRVO , oral corticosteroid , intravitreal steroid , vitrectomy , hemodilution , intravitreal tissue plasminogen activator , hyperbaric oxygen , laser surgical chorioretinal anastomosis . Studies demonstrate effectiveness treatment inconclusive , although benefit suggest recent report . In recent study benefit antiVEGF agent improve macular edema due CRVO show . In study go compare effect intravitreal antiVEGF ( Avastin ) combination Avastin Triamcinolon improve visual acuity macular thickness patient recent ( Less 6 month ) CRVO .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>CRVO duration le 6 month vision le 20/320 vison 20/50 history galucoma diabetic retinopathy previous laser intravitreal treatment medium opacity prevents funduscopy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>CRVO</keyword>
	<keyword>Intravitreal Avastin</keyword>
	<keyword>Intravitreal triamcinolone</keyword>
</DOC>